These exosomes secreted either in HER2-positive tumor cell-conditioned supernatants or in serum of BC patients bound to trastuzumab and inhibited trastuzumab activity on SKBR3 cell proliferation, suggesting the role of HER2-positive exosomes in modulating sensitivity to trastuzumab. The gene discussed is ERBB2; the disease is neoplasm.